288,344 Celcuity, Inc. $CELC Shares Acquired by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lifted its position in Celcuity, Inc. (NASDAQ:CELC) by 10,659.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 291,049 shares of the company’s stock after acquiring an additional 288,344 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Celcuity were worth $23,144,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Parallel Advisors LLC purchased a new position in shares of Celcuity during the 1st quarter worth about $38,000. PNC Financial Services Group Inc. raised its position in Celcuity by 20.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after purchasing an additional 86 shares during the period. KBC Group NV purchased a new stake in Celcuity in the 1st quarter worth about $64,000. IFP Advisors Inc purchased a new stake in Celcuity in the 2nd quarter worth about $73,000. Finally, EverSource Wealth Advisors LLC lifted its stake in Celcuity by 139.1% in the first quarter. EverSource Wealth Advisors LLC now owns 820 shares of the company’s stock worth $94,000 after purchasing an additional 477 shares during the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CELC has been the subject of several recent analyst reports. Royal Bank Of Canada lowered Celcuity to a “neutral” rating in a research report on Wednesday, October 28th. Zacks Research cut Celcuity from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a report on Tuesday, September 1st. Guggenheim assumed coverage on Celcuity in a research note on Friday, November 6th. They set a “buy” rating and a $169.00 price target for the company. Finally, Citizens Jmp restated a “market outperform” rating and set a $177.00 price objective on shares of Celcuity in a report on Monday, August 17th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $151.79.

Celcuity Stock Down 4.1%

Shares of CELC opened at $64.32 on Thursday. The firm has a fifty day moving average price of $73.75 and a 200-day moving average price of $98.74. The company has a debt-to-equity ratio of 6.04, a current ratio of 14.62 and a quick ratio of 8.93. Celcuity, Inc. has a 12-month low of $53.54 and a 12-month high of $151.02.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($1.21) EPS for the quarter, topping the consensus estimate of ($1.51) by $0.30. On average, equities analysts expect that Celcuity, Inc. will post -5.01 EPS for the current year.

Celcuity Profile

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.